Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol

Cancer Investigation

Volumn 28, Issue 1, 2010, Pages 23-32

  Zhu, Hong ^a   Ding, Wan Jing ^a   Wu, Rui ^a   Weng, Qin Jie ^a   Lou, Jian Shu ^a   Jin, Rong Jia ^a   Lu, Wei ^b   Yang, Bo ^a   He, Qiao Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Anti cancer; Apoptosis; Celastrol; Combination index; Combination therapy; TRAIL APO 2L

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CELASTROL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; LUNG CANCER; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; MICE; MICE, NUDE; NEOPLASMS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRITERPENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72449169529     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903095664     Document Type: Article

References (28)

1. Yang, H.; Chen, D.; Cui, Q.C.; Yuan, X.; Dou, Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006, 66(9), 4758- 4765.
2. Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C.-G.; Sun, D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008, 7(1), 162-170.
3. Zhang, X.D.; Nguyen, T.; Thomas, W.D.; Sanders, J.E.; Hersey, P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000, 482(3), 193-199.
4. Pan, G.; Ni, J.;Wei, Y.F.; Yu,G.; Gentz, R.; Dixit, V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277(5327), 815-818.
5. Pan, G.; O'Rourke, K.; Chinnaiyan, A.M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276(5309), 111-113.
6. Sheridan, J.P.; Marsters, S.A.; Pitti, R.M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C.L.; Baker, K.; Wood, W.I.; Goddard, A.D.; Godowski, P.; Ashkenazi, A. Control of TRAILinduced apoptosis by a family of signaling and decoy receptors. Science 1997, 277(5327), 818-821.
7. Ozoren, N.; Fisher, M.J.; Kim, K.; Liu, C.X.; Genin, A.; Shifman, Y.; Dicker, D.T.; Spinner, N.B.; Lisitsyn, N.A.; El-Deiry, W.S. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 2000, 16(5), 917-925.
8. Wang, S.; El-Deiry, W.S. TRAIL and apoptosis induction by TNFfamily death receptors. Oncogene 2003, 22(53), 8628-18233
9. Cuello, M.; Ettenberg, S.A.; Nau, M.M.; Lipkowitz, S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001, 81(3), 380-390.
10. Ray, S.; Shyam, S.; Fraizer, G.C.; Almasan, A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther 2007, 6(4), 1368-1378.
11. Jung, E.M.; Lim, J.H.; Lee, T.J.; Park, J.-W.; Choi, K.S.; Kwon, T.K. Curcumin sensitizes tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 2005, 26(11), 1905-1913.
12. Luo, P.; He, Q.; He, X.; Hu, Y.; Lu, W.; Cheng, Y.; Yang, B. Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol Cancer Ther 2006, 5(4), 962-968.
13. Yang, F.; Chen, Y.; Duan, W.; Zhang, C.; Zhu, H.; Ding, J. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer 2006, 119(5), 1184-1193.
14. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22, 27-55.
15. Chou, T.C.; Talalay, P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981, 115, 207-216.
16. Kang, M.H.; Kang, Y.H.; Szymanska, B.; Wilczynska-Kalak U.; Sheard M.A.; Harned T.M.; Lock R.B.; Reynolds C.P. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110(6), 2057-2066.
17. Ruiz-Ruiz, C.; Lopez-Rivas, A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J 2002, 365(Pt 3), 825-832.
18. Sandra, F.; Hendarmin, L.; Nakao, Y.; Nakamura, N.; Nakamura, S. TRAIL cleaves caspase-8, -9 and -3 of AM-1 cells: a possible pathway for TRAIL to induce apoptosis in ameloblastoma. Tumour Biol 2005, 26(5), 258-264.
19. Ashkenazi, A.; Dixit, V.M. Death receptors: signaling and modulation. Science 1998, 281(5381), 1305-1308.
20. El-Deiry, W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001, 8(11), 1066-1075.
21. Ashkenazi, A.; Pai, R.C.; Fong, S.; Leung, S.; Lawrence, D.A.; Marsters, S.A.; Blackie, C.; Chang, L.; McMurtrey, A.E.; Hebert, A.; DeForge, L.; Koumenis, I.L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104(2), 155-162.
22. Keane, M.M.; Ettenberg, S.A.; Nau, M.M.; Russell, E.K.; Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999, 59(3), 734-741.
23. Kim, M.; Liao, J.; Dowling, M.L.; Voong, K.R.; Parker, S.E.; Wang, S.; El-Deiry, W.S.; Kao, G.D. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res 2008, 68(9), 3440-3449.
24. Zhang, L.; Gu, J.; Lin, T.; Huang, X.; Roth, J.A.; Fang, B. Mechanisms involved in development of resistance to adenovirusmediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther 2002, 9(18), 1262-1270.
25. Nagase, M.; Oto, J.; Sugiyama, S.; Yube, K.; Takaishi, Y.; Sakato, N. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 2003, 67(9), 1883-1887.
26. Sethi, G.; Ahn, K.S.; Pandey, M.K.; Aggarwal, B.B. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007, 109(7), 2727-2735.
27. Ashkenazi, A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer 2002, 2(6), 420-430.
28. Zhao, L.; Wientjes, M.G.; Au, J.L.S. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004, 10(23), 7994-8004